CAD and acute myeloid leukemia: CAD, the enzyme that initiates de novo pyrimidine synthesis, was downregulated acutely by decitabine or 5-azacytidine, likely because of terminal-differentiation of most of the AML cells, but was upregulated at stable resistance to decitabine.